Table 1.
Characteristics and health status of COPD subjects at baseline according to the exacerbation status during the 6-month follow-up*
| With exacerbation (n = 48) |
Without exacerbation (n = 108) |
P value | |
| Gender (M/F) | 46/2 | 103/5 | 0.90 |
| Age, yrs | 71.4 ± 7.0 | 71.4 ± 6.0 | 0.95 |
| pre-bronchodilator FEV1, L | 0.83 ± 0.22 | 1.04 ± 0.37 | < 0.001 |
| pre-bronchodilator FEV1, %pred. | 32.8 ± 9.1 | 40.5 ± 13.3 | <0.001 |
| pre-bronchodilator FVC, L | 2.06 ± 0.42 | 2.26 ± 0.66 | 0.049 |
| post-bronchodilator FEV1, L | 1.04 ± 0.26 | 1.26 ± 0.43 | <0.001 |
| post-bronchodilator FEV1, %pred. | 40.7 ± 10.9 | 49.3 ± 15.4 | <0.001 |
| post-bronchodilator FVC, L | 2.50 ± 0.46 | 2.67 ± 0.66 | 0.10 |
| Current/former-smokers | 10/38 | 18/90 | 0.53 |
| Using inhaled corticosteroids, % | 54.2 | 49.1 | 0.57 |
| TLC, L | 5.78 ± 0.88 | 5.60 ± 1.00 | 0.28 |
| RV/TLC, % | 50.4 ± 7.3 | 47.0 ± 8.7 | 0.02 |
| KCO, mmol·min-1·kPa-1·L-1 | 0.83 ± 0.38 | 0.99 ± 0.39 | 0.02 |
| PaO2, kPa | 9.71 ± 1.20 | 9.81 ± 1.17 | 0.62 |
| PaCO2, kPa | 5.48 ± 0.41 | 5.40 ± 0.52 | 0.37 |
| CRQ** | |||
| Dyspnea (5–35) | 25.4 ± 5.4 | 27.0 ± 5.2 | 0.09 |
| Fatigue (4–28) | 19.0 ± 5.3 | 20.3 ± 5.4 | 0.19 |
| Emotion (7–49) | 37.4 ± 8.5 | 39.4 ± 8.6 | 0.18 |
| Mastery (4–28) | 22.0 ± 4.4 | 22.4 ± 4.6 | 0.60 |
| Total (20–140) | 103.8 ± 20.2 | 109.0 ± 20.3 | 0.14 |
| SGRQ (0–100)† | |||
| Symptoms | 53.7 ± 20.7 | 45.2 ± 22.8 | 0.03 |
| Activity | 54.4 ± 19.8 | 43.1 ± 23.3 | 0.003 |
| Impacts | 32.8 ± 18.9 | 26.9 ± 19.1 | 0.08 |
| Total score | 44.5 ± 17.7 | 36.2 ± 19.4 | 0.013 |
* The data are presented as mean ± SD unless otherwise stated. ** Higher scores indicate a better quality of life on the CRQ. † Higher scores indicate a poorer health status on the SGRQ.